Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

A trip down memory lane with Retrovirology.

Benkirane M, Berkhout B, Borrow P, Fassati A, Fujii M, Garcia-Martinez JV, Margolis D, Nijhuis M, Parent L, Strebel K, Venter F, Kirchhoff F, Lever A, Ross S, Mak J.

Retrovirology. 2019 Aug 21;16(1):22. doi: 10.1186/s12977-019-0485-y. No abstract available.

2.

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.

Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, Martinez-Picado J, Nijhuis M, Wensing AMJ, Lee H, Grant P, Nastouli E, Lambert J, Pace M, Salasc F, Monit C, Innes AJ, Muir L, Waters L, Frater J, Lever AML, Edwards SG, Gabriel IH, Olavarria E.

Nature. 2019 Apr;568(7751):244-248. doi: 10.1038/s41586-019-1027-4. Epub 2019 Mar 5.

3.

Development of sensitive ddPCR assays to reliably quantify the proviral DNA reservoir in all common circulating HIV subtypes and recombinant forms.

Bosman KJ, Wensing AM, Pijning AE, van Snippenberg WJ, van Ham PM, de Jong DM, Hoepelman AI, Nijhuis M.

J Int AIDS Soc. 2018 Sep;21(9):e25185. doi: 10.1002/jia2.25185.

4.

Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant.

Salgado M, Kwon M, Gálvez C, Badiola J, Nijhuis M, Bandera A, Balsalobre P, Miralles P, Buño I, Martinez-Laperche C, Vilaplana C, Jurado M, Clotet B, Wensing A, Martinez-Picado J, Diez-Martin JL; IciStem Consortium.

Ann Intern Med. 2018 Nov 20;169(10):674-683. doi: 10.7326/M18-0759. Epub 2018 Oct 16. Erratum in: Ann Intern Med. 2019 Jan 1;170(1):80.

PMID:
30326031
5.

Rapid Rebound of a Preexisting CXCR4-tropic Human Immunodeficiency Virus Variant After Allogeneic Transplantation With CCR5 Δ32 Homozygous Stem Cells.

Verheyen J, Thielen A, Lübke N, Dirks M, Widera M, Dittmer U, Kordelas L, Däumer M, de Jong DCM, Wensing AMJ, Kaiser R, Nijhuis M, Esser S.

Clin Infect Dis. 2019 Feb 1;68(4):684-687. doi: 10.1093/cid/ciy565.

PMID:
30020413
6.

All-printed cell counting chambers with on-chip sample preparation for point-of-care CD4 counting.

Wasserberg D, Zhang X, Breukers C, Connell BJ, Baeten E, van den Blink D, S O L À Benet È, Bloem AC, Nijhuis M, Wensing AMJ, Terstappen LWMM, Beck M.

Biosens Bioelectron. 2018 Oct 15;117:659-668. doi: 10.1016/j.bios.2018.07.002. Epub 2018 Jul 3.

7.

Digital PCR as a tool to measure HIV persistence.

Rutsaert S, Bosman K, Trypsteen W, Nijhuis M, Vandekerckhove L.

Retrovirology. 2018 Jan 30;15(1):16. doi: 10.1186/s12977-018-0399-0. Review.

8.

Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.

Fun A, Leitner T, Vandekerckhove L, Däumer M, Thielen A, Buchholz B, Hoepelman AIM, Gisolf EH, Schipper PJ, Wensing AMJ, Nijhuis M.

Retrovirology. 2018 Jan 5;15(1):1. doi: 10.1186/s12977-017-0384-z.

9.

Professor Mark Wainberg.

Benkirane M, Berkhout B, Borrow P, Fassati A, Fujii M, Garcia JV, Gorry P, Lever A, Mak J, Nijhuis M, Strebel K, Venter F, Weiss R.

Retrovirology. 2017 May 5;14(1):30. doi: 10.1186/s12977-017-0353-6. No abstract available.

10.

High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients.

Hofstra LM, Sánchez Rivas E, Nijhuis M, Bank LEA, Wilkinson E, Kelly K, Mudrikova T, Schuurman R, de Oliveira T, de Kort J, Wensing AMJ.

Clin Infect Dis. 2017 Apr 15;64(8):1092-1097. doi: 10.1093/cid/cix056.

11.

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates.

Ray N, Li T, Lin Z, Protack T, van Ham PM, Hwang C, Krystal M, Nijhuis M, Lataillade M, Dicker I.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):52-60. doi: 10.1097/QAI.0000000000001304.

12.

A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape.

Lebbink RJ, de Jong DC, Wolters F, Kruse EM, van Ham PM, Wiertz EJ, Nijhuis M.

Sci Rep. 2017 Feb 8;7:41968. doi: 10.1038/srep41968.

13.

International AIDS Society global scientific strategy: towards an HIV cure 2016.

Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F; International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J.

Nat Med. 2016 Aug;22(8):839-50. doi: 10.1038/nm.4108. Epub 2016 Jul 11.

14.

CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections.

van Diemen FR, Kruse EM, Hooykaas MJ, Bruggeling CE, Schürch AC, van Ham PM, Imhof SM, Nijhuis M, Wiertz EJ, Lebbink RJ.

PLoS Pathog. 2016 Jun 30;12(6):e1005701. doi: 10.1371/journal.ppat.1005701. eCollection 2016 Jun.

15.

The presence of protective cytotoxic T lymphocytes does not correlate with shorter lifespans of productively infected cells in HIV-1 infection.

Spits HB, Mudrikova T, Schellens IM, Wensing AM, Prins JM, Feuth T, Spierings E, Nijhuis M, van Baarle D, Borghans JA.

AIDS. 2016 Jan 2;30(1):9-17. doi: 10.1097/QAD.0000000000000914.

PMID:
26731751
16.

Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.

van Lelyveld SF, Symons J, van Ham P, Connell BJ, Nijhuis M, Wensing AM, Hoepelman AI.

Int J Antimicrob Agents. 2016 Jan;47(1):84-90. doi: 10.1016/j.ijantimicag.2015.09.013. Epub 2015 Oct 25.

PMID:
26585497
17.

Comparison of digital PCR platforms and semi-nested qPCR as a tool to determine the size of the HIV reservoir.

Bosman KJ, Nijhuis M, van Ham PM, Wensing AM, Vervisch K, Vandekerckhove L, De Spiegelaere W.

Sci Rep. 2015 Sep 9;5:13811. doi: 10.1038/srep13811.

18.

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.

van Lelyveld SF, Drylewicz J, Krikke M, Veel EM, Otto SA, Richter C, Soetekouw R, Prins JM, Brinkman K, Mulder JW, Kroon F, Middel A, Symons J, Wensing AM, Nijhuis M, Borghans JA, Tesselaar K, Hoepelman AI; MIRS study group.

PLoS One. 2015 Jul 24;10(7):e0132430. doi: 10.1371/journal.pone.0132430. eCollection 2015.

19.

Short Communication: In Vitro Accumulation of Drug Resistance Mutations in Chimeric Infectious Clones Containing Subtype B or C Reverse Transcriptase and Selected with Tenofovir or Didanosine.

Cunha RD, Abreu CM, Sousa AK, Mabombo VC, Nijhuis M, de Jong D, Tanuri A.

AIDS Res Hum Retroviruses. 2015 Aug;31(8):851-8. doi: 10.1089/AID.2014.0324. Epub 2015 Jul 16.

PMID:
26075306
20.

Robust regression methods for real-time polymerase chain reaction.

Trypsteen W, De Neve J, Bosman K, Nijhuis M, Thas O, Vandekerckhove L, De Spiegelaere W.

Anal Biochem. 2015 Jul 1;480:34-6. doi: 10.1016/j.ab.2015.04.001. Epub 2015 Apr 8.

PMID:
25862086
21.

Near Full-Length Characterization and Population Dynamics of the Human Immunodeficiency Virus Type I Circulating Recombinant Form 42 (CRF42_BF) in Luxembourg.

Struck D, Roman F, De Landtsheer S, Servais JY, Lambert C, Masquelier C, Venard V, Ruelle J, Nijhuis M, Schmit JC, Seguin-Devaux C.

AIDS Res Hum Retroviruses. 2015 May;31(5):554-8. doi: 10.1089/AID.2014.0364. Epub 2015 Mar 6.

PMID:
25654164
22.

Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.

Pingen M, Wensing AM, Fransen K, De Bel A, de Jong D, Hoepelman AI, Magiorkinis E, Paraskevis D, Lunar MM, Poljak M, Nijhuis M, Boucher CA; SPREAD programme.

Retrovirology. 2014 Nov 29;11:105. doi: 10.1186/s12977-014-0105-9.

23.

Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model.

Pingen M, Sarrami-Forooshani R, Wensing AM, van Ham P, Drewniak A, Boucher CA, Geijtenbeek TB, Nijhuis M.

Retrovirology. 2014 Dec 14;11:113. doi: 10.1186/s12977-014-0113-9.

24.

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.

Hofstra LM, Nijhuis M, Mudrikova T, Fun A, Schipper P, Schneider M, Wensing A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19755. doi: 10.7448/IAS.17.4.19755. eCollection 2014.

25.

Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.

Hofstra LM, Mudrikova T, Stam AJ, Otto S, Tesselaar K, Nijhuis M, Wensing AM.

PLoS One. 2014 Oct 29;9(10):e110749. doi: 10.1371/journal.pone.0110749. eCollection 2014.

26.

Complex T-cell receptor repertoire dynamics underlie the CD8+ T-cell response to HIV-1.

Costa AI, Koning D, Ladell K, McLaren JE, Grady BP, Schellens IM, van Ham P, Nijhuis M, Borghans JA, Keşmir C, Price DA, van Baarle D.

J Virol. 2015 Jan;89(1):110-9. doi: 10.1128/JVI.01765-14. Epub 2014 Oct 15.

27.

Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.

Pingen M, Nijhuis M, Mudrikova T, van Laarhoven A, Langebeek N, Richter C, Boucher CA, Wensing AM.

J Antimicrob Chemother. 2015 Feb;70(2):573-80. doi: 10.1093/jac/dku377. Epub 2014 Sep 26.

PMID:
25261422
28.

Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient.

Symons J, Vandekerckhove L, Hütter G, Wensing AM, van Ham PM, Deeks SG, Nijhuis M.

Clin Infect Dis. 2014 Aug 15;59(4):596-600. doi: 10.1093/cid/ciu284. Epub 2014 Apr 23.

29.

Combined statistical analyses for long-term stability data with multiple storage conditions: a simulation study.

Almalik O, Nijhuis MB, van den Heuvel ER.

J Biopharm Stat. 2014;24(3):493-506. doi: 10.1080/10543406.2014.888439.

PMID:
24697656
30.

GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.

Grantz Šašková K, Kozíšek M, Stray K, de Jong D, Rezáová P, Brynda J, van Maarseveen NM, Nijhuis M, Cihlár T, Konvalinka J.

J Virol. 2014 Mar;88(6):3586-90. doi: 10.1128/JVI.02688-13. Epub 2013 Dec 26.

31.

Differential genotypic evolution of HIV-1 quasispecies in cerebrospinal fluid and plasma: a systematic review.

Stam AJ, Nijhuis M, van den Bergh WM, Wensing AM.

AIDS Rev. 2013 Jul-Sep;15(3):152-61. Review.

PMID:
24002199
32.

NOD2-mediated innate immune signaling regulates the eicosanoids in atherosclerosis.

Liu HQ, Zhang XY, Edfeldt K, Nijhuis MO, Idborg H, Bäck M, Roy J, Hedin U, Jakobsson PJ, Laman JD, de Kleijn DP, Pasterkamp G, Hansson GK, Yan ZQ.

Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2193-201. doi: 10.1161/ATVBAHA.113.301715. Epub 2013 Jul 18.

PMID:
23868940
33.

Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.

McGovern RA, Symons J, Poon AF, Harrigan PR, van Lelyveld SF, Hoepelman AI, van Ham PM, Dong W, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2013 Sep;68(9):2007-14. doi: 10.1093/jac/dkt153. Epub 2013 May 14.

PMID:
23677920
34.

Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.

Ehteshami M, Nijhuis M, Bernatchez JA, Ablenas CJ, McCormick S, de Jong D, Jochmans D, Götte M.

J Biol Chem. 2013 Jun 14;288(24):17336-46. doi: 10.1074/jbc.M112.433441. Epub 2013 Apr 18.

35.

Evolution and viral characteristics of a long-term circulating resistant HIV-1 strain in a cluster of treatment-naive patients.

Hofstra LM, Nijhuis M, Pingen M, Mudrikova T, Riezebos-Brilman A, Simoons-Smit AM, Van Ham PM, Bierman WF, Wensing AM.

J Antimicrob Chemother. 2013 Jun;68(6):1246-50. doi: 10.1093/jac/dkt038. Epub 2013 Mar 6.

PMID:
23467175
36.

Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis.

Messiaen P, Wensing AM, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L.

PLoS One. 2013;8(1):e52562. doi: 10.1371/journal.pone.0052562. Epub 2013 Jan 9. Review.

37.

Differential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and C.

Cunha RD, Abreu CM, Gonzalez LM, Nijhuis M, de Jong D, Aguiar RS, Afonso AO, Brindeiro RM, Tanuri A.

PLoS One. 2012;7(10):e46622. doi: 10.1371/journal.pone.0046622. Epub 2012 Oct 3.

38.

Forest fires: Burn out.

Nijhuis M.

Nature. 2012 Sep 20;489(7416):352-4. doi: 10.1038/489352a. No abstract available.

PMID:
22996530
39.

Correlation of coreceptor usage and disease progression.

Verhofstede C, Nijhuis M, Vandekerckhove L.

Curr Opin HIV AIDS. 2012 Sep;7(5):432-9. doi: 10.1097/COH.0b013e328356f6f2. Review.

PMID:
22871636
40.

Human Immunodeficiency Virus Gag and protease: partners in resistance.

Fun A, Wensing AM, Verheyen J, Nijhuis M.

Retrovirology. 2012 Aug 6;9:63. doi: 10.1186/1742-4690-9-63. Review.

41.

Which species will live?

Nijhuis M.

Sci Am. 2012 Aug;307(2):74-9. No abstract available.

PMID:
22844856
42.

Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.

van Maarseveen NM, Andersson D, Lepšík M, Fun A, Schipper PJ, de Jong D, Boucher CA, Nijhuis M.

Retrovirology. 2012 Apr 1;9:29. doi: 10.1186/1742-4690-9-29.

43.

Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans.

van Maarseveen NM, Wensing AM, de Jong D, Beilhartz GL, Obikhod A, Tao S, Pingen M, Arends JE, Hoepelman AI, Schinazi RF, Götte M, Nijhuis M.

Antivir Ther. 2011;16(7):1123-30. doi: 10.3851/IMP1912.

PMID:
22024528
44.

Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice.

Symons J, Vandekerckhove L, Paredes R, Verhofstede C, Bellido R, Demecheleer E, van Ham PM, van Lelyveld SF, Stam AJ, van Versendaal D, Nijhuis M, Wensing AM.

Clin Microbiol Infect. 2012 Jun;18(6):606-12. doi: 10.1111/j.1469-0691.2011.03631.x. Epub 2011 Sep 9.

45.

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.

Fun A, van Maarseveen NM, Pokorná J, Maas RE, Schipper PJ, Konvalinka J, Nijhuis M.

Retrovirology. 2011 Aug 24;8:70. doi: 10.1186/1742-4690-8-70.

46.

Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.

Baatz F, Nijhuis M, Lemaire M, Riedijk M, Wensing AM, Servais JY, van Ham PM, Hoepelman AI, Koopmans PP, Sprenger HG, Devaux C, Schmit JC, Perez Bercoff D.

PLoS One. 2011;6(7):e21535. doi: 10.1371/journal.pone.0021535. Epub 2011 Jul 8.

47.

Evolutionary pathways of transmitted drug-resistant HIV-1.

Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, Wensing AM.

J Antimicrob Chemother. 2011 Jul;66(7):1467-80. doi: 10.1093/jac/dkr157. Epub 2011 Apr 18. Review.

PMID:
21502281
48.

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.

Symons J, van Lelyveld SF, Hoepelman AI, van Ham PM, de Jong D, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2011 Apr;66(4):890-5. doi: 10.1093/jac/dkq535. Epub 2011 Jan 28.

PMID:
21393136
49.

Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.

Fun A, Van Baelen K, van Lelyveld SF, Schipper PJ, Stuyver LJ, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2010 Nov;65(11):2300-4. doi: 10.1093/jac/dkq319. Epub 2010 Aug 24.

PMID:
20736234
50.

HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy.

von Wyl V, Ehteshami M, Demeter LM, Bürgisser P, Nijhuis M, Symons J, Yerly S, Böni J, Klimkait T, Schuurman R, Ledergerber B, Götte M, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2010 Sep 1;51(5):620-8. doi: 10.1086/655764.

Supplemental Content

Loading ...
Support Center